June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Progression of myopia with novel myopia control spectacle lenses
Author Affiliations & Notes
  • Rebecca Weng
    Brien Holden Vision Institute, Sydney, New South Wales, Australia
  • Huy Dinh Minh Tran
    Brien Holden Vision Institute, Sydney, New South Wales, Australia
    Haiyen Eye Care, Ho Chi Minh City, Viet Nam
  • Daniel P Spiegel
    R&D Vision Sciences AMERA, Essilor International SAS, Singapore, Singapore, Singapore
  • Bjorn Drobe
    R&D Vision Sciences AMERA, Essilor International SAS, Singapore, Singapore, Singapore
  • Thomas John Naduvilath
    Brien Holden Vision Institute, Sydney, New South Wales, Australia
  • Padmaja Sankaridurg
    Brien Holden Vision Institute, Sydney, New South Wales, Australia
    University of New South Wales, Sydney, New South Wales, Australia
  • Footnotes
    Commercial Relationships   Rebecca Weng Essilor R&D Centre, Singapore, Code F (Financial Support); Huy Tran Essilor R&D Centre, Singapore, Code F (Financial Support); Daniel Spiegel Essilor R&D Centre, Singapore, Code E (Employment); Bjorn Drobe Essilor R&D Centre, Singapore, Code E (Employment), Essilor R&D Centre, Singapore, Code P (Patent); Thomas Naduvilath Essilor R&D Centre, Singapore, Code F (Financial Support); Padmaja Sankaridurg Essilor R&D Centre, Singapore, Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 252 – A0106. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rebecca Weng, Huy Dinh Minh Tran, Daniel P Spiegel, Bjorn Drobe, Thomas John Naduvilath, Padmaja Sankaridurg; Progression of myopia with novel myopia control spectacle lenses. Invest. Ophthalmol. Vis. Sci. 2022;63(7):252 – A0106.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the progression of myopia in children wearing novel spectacles with highly aspherical lenslets (HAL) versus conventional single-vision spectacles (SV) in a randomized, double-masked, and cross-over trial.

Methods : 119 Vietnamese children, aged 7 to 13 years with baseline (BL) refractive error ranging from -0.75 to -4.75D, cylinder ≤ 1.50D were assigned to 2 groups to wear either HAL or SV, and after 6 months (Stage 1) crossed over to wear the other lens type for another 6 months (Stage 2). At the end of stage 2, all children (n=105) wore HAL for a further 6 months. Based on the order in which they wore the lenses at each stage, Group I was designated HSH (HAL - SV – HAL) and Group 2 SHH (SV-HAL-HAL). Cycloplegic autorefraction was performed at BL and then every 6 months and axial length (AL) measurements were collected at BL and 3 monthly thereafter. Myopia progression (change in spherical equivalent refractive error (SE) and AL) was compared between groups. A linear mixed model with subject random intercept (adjusted for confounders -age, gender, parental myopia) was used for analysis. Post hoc multiple comparisons were Bonferroni corrected. The level of significance was set at 5%.

Results : During stages 1 and 2, myopia progressed slower with HAL than SV (significant for AL for both stages and SE for Stage 2). In the HSH group, myopia progression with SV during Stage 2 was not different to SV progression observed at Stage 1 SHH group (p=0.208 and 0.092 for SE and AL respectively) and indicates no rebound of myopia. In the SHH group, Stage 3 change in SE with HAL was greater compared to stage 2 (p<0.001) but not for AL. Children reported long hours of wearing (>13 hrs/day) and there were no subjective issues with lens wear.

Conclusions : HAL spectacles slow myopia. This is evidenced by a) inter-group comparisons at Stages 1 and 2, and b) intragroup comparison when children switched between HAL and SV between stages. Children were compliant with lens wear and in this short-term, cross-over study there was no rebound when children were switched from HAL to SV. The reduced SE change with prolonged wear of HAL (Stage 2 to Stage 3 in the SHH group) needs further exploration.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

The adjusted change in SE and AL (95% CI) for the two groups by stage

The adjusted change in SE and AL (95% CI) for the two groups by stage

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×